GOT2 and acute kidney injury: Finally, sequential measurement of these AKI biomarkers or other AKI biomarkers (e.g., kidney injury molecule-1, liver fatty acid-binding proteins) and scoring systems (e.g., daily, weekly) may reflect the dynamic aspects of clinical diseases and thus provide superior information on mortality risk.